Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Other Non Operating Income: 2010-2025

Historic Other Non Operating Income for OptimizeRx (OPRX) over the last 9 years, with Q3 2025 value amounting to $62000.0.

  • OptimizeRx's Other Non Operating Income rose 6315.79% to $62000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $175000.0, marking a year-over-year decrease of 691.49%. This contributed to the annual value of $152000.0 for FY2024, which is 6960.0% down from last year.
  • Per OptimizeRx's latest filing, its Other Non Operating Income stood at $62000.0 for Q3 2025, which was up 6315.79% from $37000.0 recorded in Q2 2025.
  • Over the past 5 years, OptimizeRx's Other Non Operating Income peaked at $720419.0 during Q2 2023, and registered a low of -$1.6 million during Q4 2023.
  • Its 5-year average for Other Non Operating Income is $92182.0, with a median of $38500.0 in 2024.
  • Examining YoY changes over the last 5 years, OptimizeRx's Other Non Operating Income showed a top increase of 2218230000.0% in 2023 and a maximum decrease of 39230.19% in 2023.
  • Over the past 5 years, OptimizeRx's Other Non Operating Income (Quarter) stood at $2382.0 in 2021, then soared by 22507.56% to $538512.0 in 2022, then crashed by 392.3% to -$1.6 million in 2023, then skyrocketed by 102.48% to $39000.0 in 2024, then skyrocketed by 58.97% to $62000.0 in 2025.
  • Its Other Non Operating Income was $62000.0 in Q3 2025, compared to $37000.0 in Q2 2025 and $39000.0 in Q1 2025.